The Journal of Cell BiologyMolecular BiologyPeer-reviewed journal article
The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity
Adrienne E.D. StormoiD, Farbod ShavarebiiD, Molly FitzGibbon, Elizabeth M. Earley, Hannah D. AhrendtiD, Lotus LumiD, Erik VerschuereniD, Danielle L. SwaneyiD, Gaia Skibinski, Abinaya RavisankariD, Jeffrey van HareniD, Emily J. DavisiD, Jeffrey R. JohnsoniD, John Von DolleniD, Carson BaleniD, Jacob PorathiD, Claudia CrosioiD, Christian MirescuiD, Ciro IaccarinoiD, William T. DaueriD, R. Jeremy NicholsiD, Torsten WittmanniD, Timothy C. CoxiD, Steven M. FinkbeineriD, Nevan J. KroganiD, , Annie OF HinikeriD
Abstract
Missense mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of familial Parkinsons Disease (PD); however, pathways regulating LRRK2 subcellular localization, function, and turnover are not fully defined. We performed quantitative mass spectrometry-based interactome studies to identify 48 novel LRRK2 interactors, including the microtubule-associated E3 ubiquitin ligase TRIM1 (Tripartite Motif Family 1). TRIM1 recruits LRRK2 to the microtubule cytoskeleton for ubiquitination and proteasomal degradation by binding LRRK2911-920, a nine amino acid segment within a flexible interdomain region (LRRK2853-981), which we designate the "Regulatory Loop" (RL). Phosphorylation of LRRK2 Ser910/Ser935 within LRRK2 RL serves as a molecular switch controlling LRRK2s association with cytoplasmic 14-3-3 versus microtubule-bound TRIM1. Association with TRIM1 modulates LRRK2s interaction with Rab29 and prevents upregulation of LRRK2 kinase activity by Rab29 in an E3-ligase-dependent manner. Finally, TRIM1 rescues neurite outgrowth deficits caused by PD-driving mutant LRRK2 G2019S. Our data suggest that TRIM1 is a critical regulator of LRRK2, controlling its degradation, localization, binding partners, kinase activity, and cytotoxicity.
- Citations
- 20
- FWCI
- 2.24
- Field percentile
- top 11%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- 14-3-3 binding maintains the Parkinson's associated kinase LRRK2 in an inactive state
Juliana A. Martinez Fiesco, Alexandra G. Beilina, … Ping Zhang·Nature CommunicationsPeer-reviewed·Aug 5, 2025
- 14-3-3 phosphorylation inhibits 14-3-3theta's ability to regulate LRRK2 kinase activity
Rudradip Pattanayak, Chad M. Petit, Talene A. Yacoubian·bioRxiv·May 27, 2023
- Structural basis for Parkinson's Disease-linked LRRK2's binding to microtubules
D. M. Snead, M. Matyszewski, … S. L. Reck-Peterson·bioRxiv·Jan 21, 2022
- Structural basis of human LRRK2 membrane recruitment and activation
H. Zhu, F. Tonelli, … J. Sun·bioRxiv·Apr 26, 2022
- Parkinson's Disease-linked LRRK2 structure and model for microtubule interaction
C. K. Deniston, J. Salogiannis, … A. E. Leschziner·bioRxiv·Jan 6, 2020
- LRRK2/LRRK1 interactions modulate Rab7 activity and inhibit lysosomal exocytosis
Madiha Mohieldin Merghani, Ellen Gerhardt, … Tiago F. Outeiro·bioRxiv·Jun 15, 2026